Commit Biologics’ Post

Sweet Basil plant's internal messengers wield a remarkable power: annihilating human cancer cells. Explore the findings in our latest publication in Wiley's Journal of Extracellular Biology. Nature's messengers, extracellular vesicles, enable plant cells to communicate. Unleashing their potential, we've harnessed these tiny powerhouses to combat cancer with significant potency. Witness the impact of sweet basil particles as they engage in cross-species combat against pancreatic cancer, showcasing unparalleled killing properties. #ISEV #JexBio #JExBio #plantscience #cancerresearch #pharmaceuticals #Pennmedicine #Upenn https://lnkd.in/esTsQpft

Today, we announced preclinical data for potential first-in-class medicines, including FHD-909, a BRM (SMARCA2) selective inhibitor, and our selective CBP degrader and selective EP300 degrader programs at the 2024 American Association for Cancer Research Annual Meeting. Learn about the data, and don't forget to register for the webcast at 5 pm ET: https://bit.ly/4aOkbZz #biotechnology #innovation #oncology #drugdevelopment #AACR24

TPX-0005 (Macrocyclic Compound): A Next-Generation ROS1/TRK/ALK Inhibitor Author: Peng Li Reviewer & Editor: Lisha Wang [Full Article]：https://lnkd.in/dKz_5ZxH TPX-0005 (Repotrectinib) is a next-generation tyrosine kinase inhibitor targeting ROS1, TRK, and ALK proteins, specifically developed to overcome drug resistance in non-small cell lung cancer (NSCLC). It has demonstrated significant efficacy, particularly in ROS1-positive, TKI-naive patients, with an objective response rate of 79%. Approved by the FDA in November 2023 under the brand name Augtyro, it also has ongoing applications in the EU and Asia. The drug’s compact macrocyclic structure was designed to overcome clinic acquired resistance of the first-generation inhibitors Larotrectinib (LOXO-101) or Entrectinib. [Full Article]：https://lnkd.in/dKz_5ZxH product.pharmablock.com PharmaBlock Group; PharmaBlock (USA), Inc. #DrugDiscovery #Innovation #Biotech

#ACROHighlights [Featured Product] 🔑 Unleash the Potential of MMPs in Cancer Therapeutics 🔬 Unlock the secrets of the tumor microenvironment with our recombinant MMP proteins. Matrix Metalloproteinases (MMPs) are key players in remodeling the TME, driving tumor growth, invasion, and metastasis. Explore our premium MMP products (MMP-1, MMP-2, MMP-3, and more) to uncover new cancer research and therapeutic development frontiers. Leverage the versatile capabilities of these enzymes to propel your pharmaceutical R&D to new heights. 💊💪 🔗https://lnkd.in/gm7TPZbd #TumorMicroenvironment #MatrixMetalloproteinases #CancerResearch #Biotechnology #MMPs

When cytotoxic T cells want to kill cancer cells, they can make them self-destruct through a process called apoptosis, or programmed cell death. This happens in two ways: from outside the cell (extrinsic) or inside the cell (intrinsic). In the intrinsic pathway, a substance called granzymes is sent into the cancer cell by another protein called perforin. Once inside, granzymes cut a protein called BID, creating a shorter version of it. This shorter BID then starts a chain reaction that leads to the cancer cell destroying itself. Why is this important? By understanding and using these processes, scientists can develop treatments that specifically target and kill cancer cells. #pharma #research #biotech #medical #monitoring #qualityassurance #quality #drug 

The article "Antibody drug conjugate: the 'biological missile' for targeted cancer therapy" by Fu et al. explores the role of ADCs in targeted cancer treatment. It discusses ADC structure/mechanism, advantages over chemotherapy, and insights into development/applications. In summary, this article highlights the promise of ADCs as "biological missiles" against cancer. KSB contributes significantly through end-to-end ADC research, analytical testing, process optimization, GMP production and regulatory compliance. By leveraging our specialized expertise, we can enable manufacturing of high-quality ADCs to advance patient outcomes. Contact us to learn more! Article link: https://lnkd.in/gNN7epbY #AntibodyDrugConjugate #TargetedTherapy #CancerTreatment #CDMO

Organizations Who are Conducting Human Trials with iPSC-Derived Cellular Therapeutics - https://lnkd.in/gE3uiwby Despite their enormous promise though, no iPSC-derived cellular therapeutic has yet to receive regulatory approval in any jurisdiction worldwide. With this said, at least a dozen different entities are actively testing iPSC-derived cellular products in human trials. There are also at least 62 different companies that are developing iPSC-derived cellular therapeutics within preclinical and clinical testing environments. Learn more here: https://lnkd.in/gE3uiwby #ipscells #stemcells #celltherapies Cynata Therapeutics Fate Therapeutics Inc. Osaka University Kyoto University Masonic Cancer Center, University of Minnesota Keio University Tehran University of Medical Sciences The National Institutes of Health

🚀 Exciting News from Eisbach Bio! 🚀 We're thrilled to announce the completion of our Phase I clinical trial for our helicase inhibitor, EIS-10700, which demonstrated excellent safety, tolerability, and pharmacokinetics! 🌟 This marks the successful end of our first clinical study and we look forward to investigating the efficacy of EIS-10700 in oncology in the near future. Read the press release to learn more about the trial and stay tuned as we continue to push the boundaries of cancer medicine and synthetic lethality!💡 Link to PR: https://lnkd.in/eTC65FeW #Biotech #Pharma #ClinicalTrials #SyntheticLethality #CancerResearch #AIinMedicine

We are excited to share that RECEPTOR.AI is entering in partnership with Moexa Pharmaceuticals, Inc. to drive the discovery and development of novel small molecule therapeutics targeting protein-protein interactions (PPIs) for cancer and fibrosis treatment. This collaboration will leverage our Induced Proximity Platform, to develop PPIs modulating compounds, advancing the frontiers of AI-powered drug discovery. Together with Moexa's deep expertise in cancer and fibrosis biology, we are poised to accelerate the creation of transformative therapies. For more details, visit our website and read the full press release: https://lnkd.in/ejG7xSt7 Learn more about our Induced Proximity Platform: https://lnkd.in/eNfRMx_P #Partnership #AI #DrugDiscovery #Cancer #Fibrosis #Biotechnology #Innovation

$PTCT - Cancer Fighters asset ratings are decreasing.: Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases https://lnkd.in/gcqWbeCz #stocks #stocktwits #thematic_portfolio